Headache disorders, encompassing migraines, tension-type headaches, and cluster headaches, present a significant clinical challenge for healthcare professionals.
These disorders are primarily neurovascular, involving complex interactions between the nervous and vascular systems. Understanding these mechanisms is crucial for effective treatment.
Diagnosis is primarily clinical, relying on patient history and physical examination. Imaging studies are reserved for atypical presentations.
Management includes both pharmacological and non-pharmacological strategies. Tailoring treatment to individual patient needs is key.
Continuing research into headache disorders will undoubtedly enhance our understanding and management of these complex conditions, ultimately improving patient outcomes.
1.
Innovative oncology therapeutics are being created in collaboration between Moderna and Immatics.
2.
A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.
3.
New imaging guidelines for head and neck cancers, a step toward practice change
4.
How wildfires pose challenges to cancer care
5.
Annual whole-body, low-dose CT aids management of smoldering multiple myeloma
1.
Checkpoint Inhibitors in Oncology: Advances in PD-1/PD-L1 and CTLA-4 Targeted Therapy
2.
Mitoxantrone–Napabucasin Co-Nanoformulation Activates cGAS-STING in HCC Therapy
3.
Geriatric Medicine Through Long-Term Functional Survivorship After Cancer in Older Adults
4.
Omentum Cancer: Causes, Symptoms, and Treatment Options
5.
Advanced Directions in Oncology and Quality Improvement
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
When Unexplained Bruising May Require Blood Testing
2.
Current Scenario of Cancer- The Incidence of Cancer in Men
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I
4.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation